Lv3
378 积分 2021-01-23 加入
Announcing the Lancet Commission on colorectal cancer: addressing the rising global burden
2天前
待确认
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
4天前
已完结
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
8天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
23天前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
30天前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
1个月前
已完结
Gastric Cancer: A Review
1个月前
已完结
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
1个月前
已完结
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
1个月前
已完结
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial
2个月前
已完结
皖公网安备34019202002308
